Effect of PMSCs and Their Secretome for the Treatment of GvHD

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

June 30, 2023

Study Completion Date

January 30, 2024

Conditions
GVHD
Interventions
BIOLOGICAL

Secretome (set of substances released from the cell to its surroundings) of mesenchymal stem cells retrieved from the placenta (containing 400 microgram protein/ milliliter)

Patients in the intervention arm received 6 doses of secretome of mesenchymal stem cells retrieved from the placenta (containing 400 microgram protein/ milliliter) 4 cc dissolved in albumin 20% every week for 6 weeks

OTHER

4 cc distilled water dissolved in albumin 20%

Patients in the control arm received 6 doses of 4 cc distilled water dissolved in albumin 20% every week for 6 weeks

Trial Locations (1)

5166614756

Abolfazl Barzegari, Tabriz

All Listed Sponsors
collaborator

SCARM Institute, Tabriz, Iran

OTHER_GOV

lead

Tabriz University of Medical Sciences

OTHER